ETF Holdings Breakdown of TRDA

News associated with TRDA

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 21,594 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) by 152.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 35,750 shares of the company’s stock after acquiring an additional 21,594 shares during […] - 2025-06-12 08:12:44

First Trust Advisors LP Cuts Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

First Trust Advisors LP decreased its position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) by 9.6% during the fourth quarter, HoldingsChannel reports. The firm owned 73,749 shares of the company’s stock after selling 7,800 shares during the period. First Trust Advisors LP’s holdings in Entrada Therapeutics were worth $1,275,000 at the end […] - 2025-05-08 08:54:57

Barclays PLC Has $887,000 Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Barclays PLC grew its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) by 13.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,365 shares of the company’s stock after purchasing an additional 6,255 shares during the period. Barclays PLC’s holdings in […] - 2025-05-06 07:40:49

Geode Capital Management LLC Cuts Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Geode Capital Management LLC trimmed its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) by 0.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 573,891 shares of the company’s stock after selling 2,560 shares during […] - 2025-04-23 08:06:55

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Holdings Increased by Federated Hermes Inc.

Federated Hermes Inc. boosted its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) by 3,104.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 99,814 shares of the company’s stock after purchasing an additional 96,699 shares during the period. Federated Hermes Inc. owned about […] - 2025-04-15 07:54:50

Arrowstreet Capital Limited Partnership Has $3.85 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Arrowstreet Capital Limited Partnership increased its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) by 123.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 222,520 shares of the company’s stock after acquiring an additional 122,823 shares during the quarter. Arrowstreet Capital […] - 2025-04-09 08:30:53

AlphaQuest LLC Invests $70,000 in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

AlphaQuest LLC purchased a new position in Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) in the fourth quarter, Holdings Channel reports. The institutional investor purchased 4,046 shares of the company’s stock, valued at approximately $70,000. A number of other large investors have also recently made changes to their positions in TRDA. Janus Henderson Group PLC […] - 2025-03-20 08:12:50

Entrada Therapeutics (NASDAQ:TRDA) Receives Buy Rating from HC Wainwright

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $20.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 66.39% from the company’s previous close. TRDA has been […] - 2025-02-27 08:44:55

China Universal Asset Management Co. Ltd. Makes New Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

China Universal Asset Management Co. Ltd. bought a new position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 7,931 shares of the company’s stock, valued at approximately $137,000. A number of other […] - 2025-02-04 09:03:05

TRDA institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-29	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	30,570	USD 241,503 1.6%
2025-05-29	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	1,336	USD 10,554 1.6%
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	19,474	USD 136,707
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	19,474	USD 136,707
Total =		70,854	USD 525,471

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer